Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance

Reuters

2025/09/12

<a href="https://laohu8.com/S/LPTX">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance

Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566991185"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566991185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566991185?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566991185","market":"us","top_or_hot":-1,"title":"Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL1tSqj6:1","article_id":"2566991185","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566991185","pubTimestamp":1757622705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550. As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Leap Therapeutics Inc.因股价合规面临纳斯达克退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPTX":0.9},"content_text":"Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance\n    \n\n        Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550(a)(2). As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410578-25-002072), on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}